AD Clinical Trials in Shanghai, Shanghai Municipality
352 recruitingShanghai, Shanghai Municipality, China
Showing 1–20 of 352 trials
Recruiting
Phase 2
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Advanced Solid TumorsHER2 Mutation
Bayer111 enrolled54 locationsNCT06760819
Recruiting
Phase 2
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
Metastatic Breast CancerAdvanced Breast Cancer
Fudan University160 enrolled1 locationNCT06649331
Recruiting
Not Applicable
Level I-II Axillary Irradiation in Breast Cancer With Sentinel-Node Macro-metastases
Breast CancerRadiotherapy
Fudan University1,608 enrolled15 locationsNCT07469267
Recruiting
Phase 1Phase 2
A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
Metastatic Breast CancerLocally Advanced Breast CancerBreast Cancer Stage IV+1 more
Forward Pharmaceuticals Co., Ltd.99 enrolled22 locationsNCT06064812
Recruiting
Phase 3
A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer
Early-stage or Locally Advanced HER2-positive Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.740 enrolled2 locationsNCT07196774
Recruiting
Phase 1Phase 2
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
HER2-positive Advanced Solid Tumor
DualityBio Inc.796 enrolled102 locationsNCT05150691
Recruiting
Phase 1Phase 2
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
Breast CancerOvarian CancerProstate Cancer+3 more
Acerand Therapeutics (Shanghai) Limited298 enrolled14 locationsNCT06380660
Recruiting
Phase 2
Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies
Antibody-drug ConjugatesAdvanced Solid Tumor CancerUrachal Cancer
Sheng Zhang90 enrolled1 locationNCT07309770
Recruiting
Phase 2
A Study of YL202 in Selected Patients With Advanced Solid Tumors
Breast CancerNSCLCHNSCC+1 more
MediLink Therapeutics (Suzhou) Co., Ltd.200 enrolled82 locationsNCT06107686
Recruiting
Phase 3
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
Locally Advanced or Metastatic Breast Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.460 enrolled60 locationsNCT06680921
Recruiting
Phase 1Phase 2
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
Breast CancerAdvanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.414 enrolled20 locationsNCT07169994
Recruiting
Phase 3
Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer
Locally Advanced Breast Cancer
RenJi Hospital316 enrolled1 locationNCT04254263
Recruiting
Phase 1
Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors
Breast CancerOvarian CancerProstate Cancer+4 more
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd30 enrolled2 locationsNCT06666270
Recruiting
Phase 1Phase 2
A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients
Advanced Unresectable or Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.528 enrolled1 locationNCT06555068
Recruiting
Phase 3
Neoadjuvant SNF Precision Therapy Phase III
Neoadjuvant Therapy
Fudan University404 enrolled1 locationNCT06913777
Recruiting
Phase 3
A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
Jiangsu HengRui Medicine Co., Ltd.1,600 enrolled2 locationsNCT06126640
Recruiting
Safety and Efficacy of IMPT or IMRT for Breast Cancer
Breast CancerProton TherapyIntensity Modulated Radiation Therapy+2 more
Ruijin Hospital500 enrolled1 locationNCT06826885
Recruiting
Phase 3
Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer
Advanced Breast CancerHR+/HER2- Breast Cancer
Fudan University184 enrolled1 locationNCT06447623
Recruiting
Phase 2
Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer
Breast CancerAdvanced Breast Cancer
Fudan University265 enrolled1 locationNCT05949541
Recruiting
The Association Between Radiation Dermatitis and Skin Microbiome in Breast Cancer Patients
Breast CancerSkin MicrobiomeRadiation Dermatitis+1 more
Fudan University100 enrolled1 locationNCT05032768